Skip to content
Biodatica
Start free

Investigator

Ozgur Sahin

LOXIGEN, INC. · funded by NCI, NIGMS

Companies
1

Resolved onto their grants.

Grants
4

Federal awards on file.

Non-dilutive funding
$2.2M

Summed across those awards.

First award
Dec 16, 2021

Latest Jun 8, 2023.

Companies from this work

Pre-ticker companies the crosswalk resolved onto a grant filed under this investigator. Momentum shows for the therapeutic areas your seat covers; open a dossier for the full crosswalk.

Grant record

Federal awards filed under this investigator name, newest first. Each links to the public record where the awarding agency publishes one.

  1. R42

    Developing novel LOX inhibitors to target chemotherapy resistant TNBC

    $1.1M

    Jun 8, 2023NCILOXIGEN, INC.NIH RePORTER · 11178114 (opens the source filing in a new tab)

  2. R35

    Nanomechanical studies of cells and biomolecules

    $408k

    Aug 1, 2022NIGMSCOLUMBIA UNIV NEW YORK MORNINGSIDENIH RePORTER · 11140280 (opens the source filing in a new tab)

  3. R01

    Inhibiting tumor growth and metastasis in highly aggressive breast cancers with centrosome amplification

    $339k

    Jul 1, 2022NCIMEDICAL UNIVERSITY OF SOUTH CAROLINANIH RePORTER · 11123328 (opens the source filing in a new tab)

  4. R01

    Overcoming chemoresistance in triple negative breast cancer

    $371k

    Dec 16, 2021NCIMEDICAL UNIVERSITY OF SOUTH CAROLINANIH RePORTER · 11229605 (opens the source filing in a new tab)

This page aggregates public U.S. federal grant records filed under one investigator name and the companies Biodatica has resolved onto them. Names are shown as the awarding agency filed them; grant awards are non-dilutive federal funding, not equity or valuation. Distinct people who file under the same name would appear together here. It is informational only and not investment advice. Methodology · Data sources